HRP20210108T1 - Liječenje migrene s acetil-leucinom - Google Patents

Liječenje migrene s acetil-leucinom Download PDF

Info

Publication number
HRP20210108T1
HRP20210108T1 HRP20210108TT HRP20210108T HRP20210108T1 HR P20210108 T1 HRP20210108 T1 HR P20210108T1 HR P20210108T T HRP20210108T T HR P20210108TT HR P20210108 T HRP20210108 T HR P20210108T HR P20210108 T1 HRP20210108 T1 HR P20210108T1
Authority
HR
Croatia
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
migraine
Prior art date
Application number
HRP20210108TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210108(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of HRP20210108T1 publication Critical patent/HRP20210108T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20210108TT 2017-06-14 2018-06-25 Liječenje migrene s acetil-leucinom HRP20210108T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine
EP18749124.6A EP3638370B1 (en) 2017-06-14 2018-06-25 Treatment of migraine with acetyl-leucine

Publications (1)

Publication Number Publication Date
HRP20210108T1 true HRP20210108T1 (hr) 2021-03-19

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210108TT HRP20210108T1 (hr) 2017-06-14 2018-06-25 Liječenje migrene s acetil-leucinom

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51836B1 (fr) * 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
DE602004017316D1 (de) * 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
SI1664016T1 (sl) * 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
ES2994242T3 (en) 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
HUE062729T2 (hu) 2017-03-28 2023-12-28 Intrabio Ltd Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra
IL273929B2 (en) 2017-10-18 2024-11-01 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
MA51836B1 (fr) 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
MA49396B1 (fr) 2021-03-31
DK3638370T3 (da) 2021-01-25
MA49396A (fr) 2020-04-22
KR20210013518A (ko) 2021-02-04
RU2020100475A3 (https=) 2021-10-22
CN111093772A (zh) 2020-05-01
SI3638370T1 (sl) 2021-04-30
SMT202100037T1 (it) 2021-03-15
BR112019026660A2 (pt) 2020-07-14
ZA201908087B (en) 2024-11-27
AU2018284330B2 (en) 2024-03-14
IL271211A (en) 2020-01-30
US20200253905A1 (en) 2020-08-13
PT3638370T (pt) 2021-01-26
HUE053089T2 (hu) 2021-06-28
MD3638370T2 (ro) 2021-04-30
MX2019014784A (es) 2021-11-16
JP2020526575A (ja) 2020-08-31
SG11201912146RA (en) 2020-01-30
IL271211B2 (en) 2024-01-01
AU2018284330A1 (en) 2020-01-02
KR102594130B1 (ko) 2023-10-24
EP3638370A1 (en) 2020-04-22
JP7130739B2 (ja) 2022-09-05
GB201709459D0 (en) 2017-07-26
LT3638370T (lt) 2021-03-25
EP3638370B1 (en) 2020-11-11
CY1123860T1 (el) 2022-05-27
ES2847169T3 (es) 2021-08-02
PL3638370T3 (pl) 2021-05-17
IL271211B1 (en) 2023-09-01
RS61481B1 (sr) 2021-03-31
CN111093772B (zh) 2023-11-03
CA3067321A1 (en) 2018-12-20
MX387909B (es) 2025-03-19
RU2020100475A (ru) 2021-07-14
WO2018229738A1 (en) 2018-12-20
US11471434B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
Citrome Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains
PH12022551379A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
WO2015121348A3 (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
RU2015143836A (ru) Лейцин и никотиновая кислота для снижения уровня липидов
WO2015194764A3 (ko) 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
HRP20201627T1 (hr) Postupak liječenja s tradipitantom
MX2021014029A (es) Formulaciones, fabricación y usos de imatinib.
TN2017000498A1 (en) Positive allosteric modulators of muscarinic m2 receptor
PH12019550263A1 (en) A Pharmaceutical Composition for Anaemia
HRP20210108T1 (hr) Liječenje migrene s acetil-leucinom
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
EA202090467A1 (ru) ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
ZA202000028B (en) Use of vibegron to treat overactive bladder
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
BR112018007118A2 (pt) método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
EP4442315A3 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
ZA202103209B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
PE20120122A1 (es) Composicion farmaceutica que comprende un analgesico y vitaminas
WO2017161402A8 (en) Formulation and method for the prevention and/or treatment of hangover symptoms